Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sheep kappa-casein peptides inhibit platelet aggregation

Z Y Qian1, P Jollès, D Migliore-Samour

  • 1Laboratoire des Protéines, CNRS URA 1188, University of Paris V, France.

Biochimica Et Biophysica Acta
|June 9, 1995
PubMed
Summary

Caseinoglycopeptide (CGP) from sheep kappa-casein effectively inhibits platelet aggregation. Specific peptide fragments of CGP show potent anti-platelet activity and demonstrate stability in plasma, suggesting therapeutic potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Study on subacute toxicity of p-chloro-m-xylenol in rats].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2025
Same author

[Construction of quality assessment index system of infection prevention and control in integrated medical and elderly care facilities].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

[A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·2024
Same author

[Study on reproductive toxicity of nano-cadmium sulfide with different particle sizes on male mice].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases·2024
Same author

Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer.

Bioactive materials·2023
Same author

[Genetic analysis of varicella-zoster virus in patients with viral anterior uveitis].

Zhonghua yi xue za zhi·2022

Area of Science:

  • Biochemistry
  • Pharmacology
  • Proteomics

Background:

  • Platelet aggregation is a key process in thrombosis.
  • Sheep kappa-casein contains bioactive peptides with potential therapeutic applications.
  • Understanding the structure-activity relationship of these peptides is crucial for drug development.

Purpose of the Study:

  • To investigate the anti-platelet activity of caseinoglycopeptide (CGP) and its derived peptides.
  • To determine the stability and in vivo behavior of CGP.
  • To compare CGP with other platelet aggregation inhibitors using computational methods.

Main Methods:

  • Enzymatic hydrolysis of CGP.
  • Reverse-phase high-performance liquid chromatography (RP-HPLC) for peptide fractionation.

Related Experiment Videos

  • In vitro platelet aggregation assays (thrombin- and collagen-induced).
  • Plasma stability assays.
  • Ex vivo pharmacokinetic study in guinea pigs.
  • Hydrophobic cluster analysis (HCA) for peptide comparison.

    • Main Results:

    • CGP dose-dependently inhibited thrombin- and collagen-induced platelet aggregation (IC50 values of 215 microM and 100 microM, respectively).
    • Three peptides (KDQDK, TAQVTSTEV, QVTSTEV) completely inhibited thrombin-induced platelet aggregation.
    • CGP exhibited prolonged stability in human and guinea-pig plasma.
    • Ex vivo studies showed 17% CGP remaining after 60 minutes post-intravenous injection in guinea pigs.
    • HCA revealed similarities between the C-terminal regions of human fibrinogen and sheep kappa-casein peptides, including the active motifs RGDF and KDQDK.

    Conclusions:

    • CGP is a potent inhibitor of platelet aggregation with potential therapeutic value.
    • Specific peptide fragments of CGP possess significant anti-platelet activity.
    • CGP demonstrates favorable pharmacokinetic properties, including plasma stability and in vivo persistence.
    • Structural similarities suggest a conserved mechanism of action for platelet aggregation inhibition across different proteins.